Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: BYSI

BeyondSpring Inc.

Healthcare | Biotechnology

No licensed closing price on file for BYSI. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

BeyondSpring Inc. (NASDAQ: BYSI) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 20:48 UTC.

What BeyondSpring Inc. does

BeyondSpring is a clinical stage biopharmaceutical company developing innovative therapies for patients with high unmet medical needs. The company's lead asset, Plinabulin, is a novel microtubule modulator that has been administered to over 700 cancer patients and works by activating immune defense mechanisms through dendritic cell maturation. Plinabulin completed a successful phase 3 study in non-small cell lung cancer and is now in a confirmatory global phase 3 study for second- and third-line NSCLC patients with specific genetic markers who progressed on prior immune checkpoint inhibitors.

Summarized from BeyondSpring Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
Return on equity556.60%

Revenue, margins & earnings

FY2021: net loss $64M on revenue $1M$1MFY2021FY2022: net loss $33M on revenue $1M$1MFY2022
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2026-07-06
Most recent filed transactions — July 2026:
  • 2026-07-06DirectorStock Options (right to buy)Award100,000—
  • 2026-07-06Chief Executive OfficerStock Options (right to buy)Award100,000—
  • 2026-05-15Chief Executive OfficerGift-260,582—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does BeyondSpring Inc. do?

BeyondSpring is a clinical stage biopharmaceutical company developing innovative therapies for patients with high unmet medical needs.

When did BYSI last file with the SEC?

BeyondSpring Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-04. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 20:48 UTC. This page is also available as JSON at /api/data?ticker=BYSI and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for BYSI and 5,000+ tickers.

Create a free account — keep BYSI
For your agent
GET /api/data?ticker=BYSI

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt